Recent developments in the inhibition of angiogenesis: Examples from studies on platelet factor-4 and the VEGF/VEGFR system

Biochemical Pharmacology

Volumn 68, Issue 6, 2004, Pages 1017-1021

  Bikfalvi, Andreas ^a  

^a UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

BCE; bovine capillary endothelial cells; CXC chemokine receptor 3 variant B; CXCR3 B; cyclic vascular endothelial growth inhibitor; cyclo VEGI; FGF; fibroblast growth factor; heparan sulfate proteoglycans; HSPGs; human umbilical vein endothelial cell; HUVEC

Indexed keywords

THROMBOCYTE FACTOR 4; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR;

ALPHA HELIX; ANGIOGENESIS; ANIMAL CELL; CELL MIGRATION; CELL PROLIFERATION; CONFERENCE PAPER; CONFORMATION; CONTROLLED STUDY; ENDOTHELIUM CELL; GENE MUTATION; GLIOMA; HUMAN; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN STRUCTURE; SURVIVAL RATE; TUMOR GROWTH;

ANGIOGENESIS INHIBITORS; ANIMALS; ENDOTHELIAL GROWTH FACTORS; HUMANS; MICE; PEPTIDES, CYCLIC; PLATELET FACTOR 4; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 4143051554     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2004.05.030     Document Type: Conference Paper

References (32)

1. Bikfalvi A., Bicknell R. Recent advances in angiogenesis, anti-angiogenesis and vascular targeting. Trends Pharmacol. Sci. 23:2002;576-582
2. Javerzat S., Auguste P., Bikfalvi A. The role of fibroblast growth factors in vascular development. Trends Mol. Med. 8:2002;483-489
3. Hagedorn M., Bikfalvi A. Target molecule for anti-angiogenesis therapy: from basic research to clinical trials. Crit. Rev. Oncol. Hematol. 34:2000;89-110
4. Folkman J. Angiogenesis inhibitors: a new class of drugs. Cancer Biol. Ther. 2(4 Suppl. 1):2003;S127-33
5. Deuel T.F., Keim P.F., Farmer M., Heinrickson R.L. Amino acid sequence of human platelet factor 4. Proc. Natl. Acad. Sci. USA. 74:1977;2256-2258
6. Stuckey J.A., St Charles R., Edwards B. A model of the platelet factor-4 complex with heparin. Proteins. 14:1992;277-287
7. Zhang X., Chen L., Bancroft D.L., Lai C.K., Maione T.M. Crystal structure of recombinant human platelet factor 4. Biochemistry. 33:1994;8361-8366
8. Maione T.E., Gray G.S., Petro J., Hunt A.J., Donner A.L., Bauer S.I., et al. Inhibition of angiogenesis by recombinant human platelet factor-4 and related peptides. Science. 247:1990;77-79
9. Sharpe R.J., Byers H.R., Scott C.F., Bauer S.I., Maione T.E. Growth inhibition of murine melanoma and human colon carcinoma by recombinant human platelet factor-4. J. Natl. Cancer Inst. 82:1990;848-853
10. Gupta S.K., Singh J.P. Inhibition of endothelial cell proliferation by platelet factor-4 involves a unique action on S phase progression. J. Cell Biol. 127:1994;1121-1127
11. Perollet C., Han Z.C., Savona C., Caen J.P., Bikfalvi A. Platelet factor 4 modulates fibroblast growth factor 2 (FGF-2) activity and inhibits FGF-2 dimerization. Blood. 91:1998;3289-3299
12. Feraud O., Cao Y., Vittet D. Embryonic stem cell-derived embryoid bodies development in collagen gels recapitulates sprouting angiogenesis. Lab. Invest. 81:2001;1669-1681
13. Hansell P., Maione T.E., Borgstrom P. Selective binding of platelet factor-4 to regions of active angiogenesis in vivo. Am. J. Physiol. 269:1995;829-836
14. Borgstrom P., Discipio R., Maione T.E. Recombinant platelet factor 4, an angiogenic marker for human breast carcinoma. Anticancer Res. 18:1998;4035-4041
15. Maione T.E., Gray G.S., Hunt A.J., Sharpe R.J. Inhibition of tumor growth in mice by an analog of platelet factor-4 that lacks affinity for heparin and retains potent angiostatic activity. Cancer Res. 51:1991;2077-2083
16. Kolber D.L., Knisely T.L., Maione T.E. Inhibition of development of murine melanoma lung metastases by systemic administration of recombinant platelet factor-4. J. Natl. Cancer Inst. 87:1995;304-309
17. Tanaka T., Manome Y., Wen P., Kufe D., Fine H.A. Viral vector-mediated transduction of a modified platelet factor-4 cDNA inhibits angiogenesis and tumor growth. Nat. Med. 3:1997;437-442
18. Jouan V., Canron X., Alemany M., et al. Modulation of in vitro angiogenesis by platelet factor-4 derived peptides and mechanism of action. Blood. 94:1999;984-993
19. Lozano R.M., Redondo-Horcajo M., Jimenez M.A., et al. Solution structure and interaction with basic and acidic fibroblast growth factor of a 3-kDa human platelet factor-4 fragment with Antiangiogenic activity. J. Biol. Chem. 276:2001;35723-35734
20. Hagedorn M., Zilberberg L., Lozano R.M., et al. A short peptide domain of platelet factor 4 blocks angiogenic key events induced by FGF-2. FASEB J. 15:2001;550-552
21. Hagedorn M., Zilberberg L., Wilting J., et al. Domain swapping in a COOH-terminal fragment of platelet factor 4 generates potent angiogenesis inhibitors. Cancer Res. 62:2002;6884-6890
22. Bello L, Lucini V, Costa F, et al. Combinatorial administration of molecules that simultaneously inhibit angiogenesis and invasion leads to increased therapeutic efficacy in mouse models of malignant glioma. Clin. Cancer Res., in press.
23. Bikfalvi A., Gimenez-Gallego G. The control of angiogenesis and tumor invasion by platelet factor-4 and platelet factor-4-derived molecules. Semin. Thromb. Hemost. 30:2004;137-144
24. Gentilini G., Kirschbaum N.E., Augustine J.A., Aster R.H., Visentin G.P. Inhibition of human umbilical vein endothelial cell proliferation by the CXC chemokine platelet factor 4 (PF4), is associated with impaired downregulation of p21(Cip1/WAF1). Blood. 93:1999;25-33
25. Sulpice E., Bryckaert M., Lacour J., Contreres J.O., Tobelem G., Tobelem G. F2-induced endothelial cell proliferation via the extracellular signal-regulated kinase pathway but not by the phosphatidylinositol 3-kinase pathway. Blood. 100:2002;3087-3094
26. Chadderton N.S., Stringer S.E. Interaction of platelet factor 4 with fibroblast growth factor 2 is stabilised by heparan sulphate. Int. J. Biochem. Cell Biol. 35:2003;1052-1055
27. 121 and VEGF165 using several concurrent mechanisms. J. Biol. Chem. 270:1995;15059-15065
28. Lasagni L., Francalanci M., Annunziato F., et al. An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4. J. Exp. Med. 197:2003;1537-1549
29. Kerbel R., Folkman J. Clinical translation of angiogenesis inhibitors. Nat. Rev. Cancer. 2:2002;727-739
30. Kerbel R.S. Antiangiogenic drugs and current strategies for the treatment of lung cancer. Semin. Oncol. 31(1 Suppl. 1):2004;54-60
31. Underiner T.L., Ruggeri B., Gingrich D.E. Development of vascular endothelial growth factor receptor (VEGFR) kinase inhibitors as anti-angiogenic agents in cancer therapy. Curr. Med. Chem. 11(6):2004;731-745
32. Zilberberg L., Shinkaruk S., Lequin O., et al. Structure and inhibitory effects on angiogenesis and tumor development of a new vascular endothelial growth inhibitor. J. Biol. Chem. 278:2003;35564-35573